Article in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
27 authors.
Andong QiuDivision of Nephrology, Department of Medicine, Columbia University, New York, New York.
Melanie ViltardDivision of Nephrology, Department of Medicine, Columbia University, New York, New York.ORCID 0000-0002-0375-0638
Rong DengDivision of Nephrology, Department of Medicine, Columbia University, New York, New York.ORCID 0000-0001-5170-3361
Jacob StauberAlbert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York.ORCID 0000-0002-9410-8527
Aryan GhotraDivision of Nephrology, Department of Medicine, Columbia University, New York, New York.
Max WerthDivision of Nephrology, Department of Medicine, Columbia University, New York, New York.
Christian HinzeKlinik für Nieren- und Hochdruckerkrankungen, Zentrum Innere Medizin, Medizinische Hochschule Hannover, Hanover, Germany.ORCID 0000-0003-2526-1621
Andrew BeenkenDivision of Nephrology, Department of Medicine, Columbia University, New York, New York.ORCID 0000-0003-1166-6716
Tian H ShenDivision of Nephrology, Department of Medicine, Columbia University, New York, New York.ORCID 0000-0001-7064-7051
Atlas KhanDivision of Nephrology, Department of Medicine, Columbia University, New York, New York.ORCID 0000-0002-6651-2725
Katherine XuDivision of Nephrology, Department of Medicine, Columbia University, New York, New York.
Abraham LevitmanAlbert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York.ORCID 0000-0002-4993-2664
Yue YuDivision of Nephrology, Department of Medicine, Columbia University, New York, New York.
Neal ParagasDivision of Nephrology, Department of Medicine, Columbia University, New York, New York.ORCID 0000-0001-6084-8220
Andrew YaehDivision of Nephrology, Department of Medicine, Columbia University, New York, New York.ORCID 0009-0006-4553-207
Beatriz Desanti de OliveiraDivision of General Medicine, Department of Medicine, Columbia University, New York, New York.ORCID 0000-0002-1352-0115
Roger W BolesDivision of Nephrology, Department of Medicine, Columbia University, New York, New York.ORCID 0000-0001-8442-0640
Efrat BruckDivision of Nephrology, Department of Medicine, Columbia University, New York, New York.
Kaitlyn CorbinDivision of Nephrology, Department of Medicine, Columbia University, New York, New York.
Kristen McNierneyDivision of Nephrology, Department of Medicine, Columbia University, New York, New York.
Lai Kuan DionneDivision of Nephrology, Department of Medicine, Washington University, St Louis, Missouri.ORCID 0000-0003-0403-7452
Christian RosenbergerKfH Dialysis Center, Erfurt, Germany.
Kai Schmidt-OttKlinik für Nieren- und Hochdruckerkrankungen, Zentrum Innere Medizin, Medizinische Hochschule Hannover, Hanover, Germany.ORCID 0000-0002-7700-7142
Thomas CarrollDepartments of Molecular Biology and Internal Medicine, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-8322-4928
Moe R MahjoubDivision of Nephrology, Department of Medicine, Washington University, St Louis, Missouri.ORCID 0000-0001-8129-7464
Rosemary SampognaDivision of Nephrology, Department of Medicine, Columbia University, New York, New York.ORCID 0000-0002-1279-4552
Jonathan BaraschDivision of Nephrology, Department of Medicine, Columbia University, New York, New York.ORCID 0000-0002-6723-9548
Funding
Transcriptional Regulation of Urothelial Differentiation During Homeostasis and Repair in Response to Urinary Tract InfectionU54DK104309 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI JONATHAN M. BARASCH, ALI G GHARAVI · 2014 to 2026
$17.7M
Structural regulation of megalin recycling in the proximal tubuleK08DK132511 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ANDREW S BEENKEN · 2023 to 2026
$666k
Human Genetic Approach for UTI Points to Novel Immune Defense Cells of the Kidney EpitheliaK01DK135917 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Katherine Xu · 2024 to 2026
$458k
Iron Delivery in the Developing KidneyR56DK092684 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BARASCH, JONATHAN M., QIU, ANDONG · 2011 to 2011
$80k
Deutsche Forschungsgemeinschaft CRC 1365Deutsche Forschungsgemeinschaft GRK 2318Deutsche Forschungsgemeinschaft RU 2841European Renal Association-European Dialysis and Transplant Association ERA PerMed (OnAKI-ICI)Irving Medical Center, Columbia University Glomerular CenterKidney Cure Carl W. Gottschalk Research Scholar AwardNIDDK NIH HHS DK073462NIDDK NIH HHS DK092684NIDDK NIH HHS DK-106548NIDDK NIH HHS DK124667/DKNIDDK NIH HHS DK-55388NIDDK NIH HHS K01 DK135917NIDDK NIH HHS K08 DK132511NIDDK NIH HHS NIH K08DK132511NIDDK NIH HHS R56DK092684NIDDK NIH HHS T32 DK108741/DKNIDDK NIH HHS U54 DK104309NIDDK NIH HHS UG3 DK114926/DK
6 · The paper itself
Abstract
key pointsTransferrin receptor 1 is critical for perinatal nephron growth and maturation; its deletion results in widespread cystic hypodysplasia. Nontransferrin bound iron traffic is a physiologic source of iron in the midgestation embryo and complements transferrin receptor 1. Cystic hypodysplasia can be rescued by exogenous iron or by the activation of systemic iron traffic with hypoxia inducible factor activators.
backgroundPericonceptual maternal iron deficiency (FeD) is a worldwide cause of premature births and low birth weights. Yet, it is unknown whether FeD affects all developing tissues equally or rather target- s pecific lineages. In addition, since FeD restricts both transferrin bound and nontransferrin bound iron species, their unique contributions to organogenesis are indeterminant.
methodsTo address questions of iron traffic and kidney development, we examined the deletion of the singular transferrin receptor ( TfR1 -/- ), created green flourescent protein-labeled TfR1 -/- embryonic stem cells for inoculation into wild blastocysts, and created TfR1 -floxed mice to generate cell autonomous deletions of TfR1 in mesenchymal, ureteric, and stromal derivatives. Finally, we created a model of global FeD with iron poor diets, for comparison with cell autonomous TfR1 deletions.
resultsTransferrin receptor deletions only modestly suppressed tubulogenesis, had little, if any effect on the growth of the ureteric bud and no gross effects on kidney stroma at mid gestation. By contrast, nutritional FeD nearly abolished kidney development, highlighting the limited phenotypes induced by transferrin receptor deletion. Yet, in the second postnatal week, the critical function of TfR1 became evident by the growth of residual TfR1 + cells that had escaped Cre-mediated deletion and by tubular segment-specific polycystic transformation. Timed treatment with iron or systemic activators of iron trafficking prevented both cystic dysplasia and the terminal loss of kidney function, reversing extensive malformations of the kidney.
conclusionsTfR1 is the critical iron species targeting postnatal tubulogenesis, but in the embryo, TfR1 must be complemented by alternative iron species called nontransferrin bound iron. Iron-deficient kidney disease is reversible postnatally.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A Switch in Iron Delivery Is Critical for Postnatal Kidney Development. · full record | OpenQuestion